Table 2.

Allogeneic sibling transplantation for severe aplastic anemia

Institution/study	Years of study	N	Age, y (median in y)	Graft rejection/failure, %	Acute GVHD,*%	Chronic GVHD, %	Actuarial survival, %
IBMTR92	1988-1992	471	20 (1-51)	16	19	32	66 at 5 y
Vienna93	1982-1996	20	25 (17-37)	0	26	53	95 at 15 y
EBMT94	1991-1998	71	19 (4-46)	3	30	35	86 at 5 y
Seoul95	1990-1999	22	22 (14-43)	5	10	33	95 at 5 y
Seoul96	1990-2001	64	28 (14-43)	18	31	19	79 at 6 y
Hamburg97	1990-2001	21	25 (7-43)	5	5	5	86 at 5 y
Paris98	1994-2001	33	20 (8-42)	6	0	42	94 at 5 y
Sao Paulo99	1993-2001	81	24 (3-53)	22	37	39	56 at 6 y
Taipei100	1985-2001	79	22 (4-43)	8	7	35	74 at 5 y
Tunis101	1998-2001	31	19 (4-39)	16	11	3	86 at 2 y
Seoul102	1995-2001	113	28 (16-50)	15	11	12	89 at 6 y
London103	1989-2003	33	17 (4-46)	24	14	4	81 at 5 y
Seattle104,105	1988-2004	94	26 (2-59)	4	24	26	88 at 6 y
Mexico City106	2000-2005	23	25 (4-65)	26	17	26	88 at 4 y

In contrast to Table 1, response rates are not provided because, in surviving patients who do not experience primary graft rejection or secondary graft failure, full hematologic recovery with donor hematopoiesis is anticipated. Only studies reporting at least 20 patients are tabulated

GVHD indicates graft-versus-host disease; IBMTR, International Blood and Marrow Transplant Registry; and EBMT, European Group for Bone Marrow Transplant

^*Results are generally for grades II to IV and patients at risk